Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Alerta

Resultados 79 results.
LastUpdate Updated on 22/11/2026 [07:34:00]
pdfxls
Results 1 to 25 of 79 nextPage  

ATHEROSCLEROTIC PLAQUE REDUCTION TREATMENTS AND COMPOSITIONS

Publication No.:  AU2025242780A1 05/11/2026
Applicant: 
REPAIR BIOTECHNOLOGIES INC [US]
REPAIR BIOTECHNOLOGIES, INC.
AU_2025242780_PA

Absstract of: AU2025242780A1

Disclosed herein are therapeutic methods and compositions for the treatment of atherosclerosis and regression of a distal atherosclerotic plaque, wherein the composition is administered to a subject and targeted to the liver.

METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING CARDIOVASCULAR DISEASE

Publication No.:  WO2026232080A1 05/11/2026
Applicant: 
THE PENN STATE RES FOUNDATION [US]
THE PENN STATE RESEARCH FOUNDATION
WO_2026232080_A1

Absstract of: WO2026232080A1

The present disclosure includes methods for preventing, treating, and monitoring cardiovascular disease based on the gut mycobiome and host genetics. Methods include: collecting a microbiome sample for a subject; analyzing the sample for a presence and abundance of a species belonging to the genus or species Kazachstania causally linked to cardiovascular disease risk by Mendelian Randomization analysis; and/or when the presence of the species belonging to Kazachstania is below a clinically relevant threshold, administering to the subject a composition including a fungal culture of Kazachstania and/or one or more cardiovascular disease medications to prevent an occurrence of or prevent further progression of the cardiovascular disease. Methods also include collecting a genetic sample from a subject and detecting the presence of cardiovascular risk-associated alleles associated with the abundance of Kazachstania. Compositions for preventing or treating a cardiovascular disease are also disclosed.

MODULATORS OF ALTERNATIVE POLYADENYLATION AND METHODS OF USE THEREOF

Publication No.:  US20260337608A1 29/10/2026
Applicant: 
THE METHODIST HOSPITAL [US]
THE METHODIST HOSPITAL
WO_2024159113_PA

Absstract of: US20260337608A1

The present disclosure relates to compositions and methods of treating, preventing, or diagnosing cardiac fibrosis and related diseases by modulating alternative polyadenylation.

BAG3 METHODS AND USES FOR TREATMENT OF CARDIAC AMYLOIDOSIS

Publication No.:  US20260335399A1 29/10/2026
Applicant: 
TEMPLE UNIV OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION [US]
TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
WO_2024059756_PA

Absstract of: US20260335399A1

Heart failure WITH Preserved Ejection Fraction (HFpEF) effects approximately three million people in the United States.

METHOD OF PREDICTION OF GESTATIONAL DIABETES MELLITUS BASED ON THE EXPRESSION PROFILE OF CARDIOVASCULAR MIRNAS

Publication No.:  US20260337660A1 29/10/2026
Applicant: 
GENESPECTOR S R O [CZ]
GENESPECTOR S.R.O.
CN_119866380_A

Absstract of: US20260337660A1

Method of prediction of gestational diabetes mellitus including both its milder and more severe form. Pregnant women are screened to determine the expression profile of two or more miRNAs in whole peripheral venous blood collected in the period of 10th-13th gestational week, whereas said two or more miRNAs are selected from the group miR-1-3p, miR-20a-5p, miR-20b-5p, miR-23a-3p, miR-100-5p, miR-125b-5p, miR-126-3p, miR-181a-5p, miR-195-5p, miR-499a-5p, and miR-574-3p.

SMALL RNA-BASED PROGNOSTIC SIGNATURES AND THERAPEUTIC COMPOSITIONS FOR CORONARY MICROVASCULAR DYSFUNCTION

Publication No.:  US20260337681A1 29/10/2026
Applicant: 
GATEHOUSE BIO INC [US]
Gatehouse Bio, Inc.
WO_2024015640_PA

Absstract of: US20260337681A1

The present disclosure provides methods and kits for evaluating and risk stratifying subjects with HFpEF. Specifically, the present disclosure provides methods and kits for determining an expression profile of small, non-coding RNA biomarkers that can predict coronary flow reserve (CFR). CFR is an important clinical measure that is correlated to the presence of coronary microvascular dysfunction (CMD) and predicts morbidity in patients diagnosed with HFpEF. In other aspects, the present disclosure provides therapeutic compositions based on the small, non-coding RNA markers, for example, with the potential to correct dysregulation of several messenger RNA targets with an sRNA mimetic, or with the potential to inhibit expression or activity of the small RNA itself with an antisense oligonucleotide. The therapeutic compositions find use in subjects with CMD and/or HFpEF.

COMPOSITIONS AND METHODS FOR DETECTING SEVERE FEVER AND THROMBOCYTOPENIA SYNDROME VIRUS

Publication No.:  EP4831302A1 28/10/2026
Applicant: 
ABBOTT LAB [US]
Abbott Laboratories
EP_4831302_A1

Absstract of: EP4831302A1

0001 Provided herein are compositions, methods, and kits for detecting Severe fever with thrombocytopenia syndrome virus (SFTSV) in human subjects. In certain embodiments, provided herein are SFTSV specific nucleic acid probes and primers, and methods for detecting SFTSV nucleic acid in human subjects.

BIOMARKERS FOR THE DIAGNOSIS OF ATRIAL FIBRILLATION CAUSE OF STROKE

Publication No.:  US20260327704A1 22/10/2026
Applicant: 
ISCHEMIA CARE LLC [US]
Ischemia Care LLC
US_20260327704_A1

Absstract of: US20260327704A1

This invention provides gene expression profiles useful for diagnosing atrial fibrillation in ischemic stroke and for distinguishing atrial fibrillation in ischemic stroke from arterial (large vessel) stroke or embolic stroke of undetermined source (ESUS).

THERAPEUTIC AGENTS FOR USE IN THE TREATMENT AND PREVENTION OF NEUROPATHY, MYOPATHY OR CARDIO(MYO)PATHY

Publication No.:  EP4824284A1 21/10/2026
Applicant: 
UNIV ANTWERPEN [BE]
Universiteit Antwerpen
WO_2025125328_A1

Absstract of: WO2025125328A1

The invention provides therapeutic agents which can be used in the treatment of neuropathy, myopathy or cardio(myo)pathy. More particularly, the invention provides compounds which are capable of stimulating autophagy, methods for identifying subjects susceptible to treatment with such compounds and methods for identifying such compounds.

USE OF PXDC1 IN PREPARATION OF PRODUCT FOR TREATING CARDIAC HYPERTROPHY

Publication No.:  WO2026213966A1 15/10/2026
Applicant: 
FUWAI HOSPITAL CHINESE ACAD OF MEDICAL SCIENCES SHENZHEN HOSPITAL SHENZHEN SUN YAT SEN CARDIOVASCULA [CN]
\u4E2D\u56FD\u533B\u5B66\u79D1\u5B66\u9662\u961C\u5916\u533B\u9662\u6DF1\u5733\u533B\u9662\uFF08\u6DF1\u5733\u5E02\u5B59\u9038\u4ED9\u5FC3\u8840\u7BA1\u533B\u9662\uFF09
WO_2026213966_A1

Absstract of: WO2026213966A1

The present invention relates to a use of PXDC1 in the preparation of a product for treating cardiac hypertrophy. The efficacy of inhibiting PXDC1 expression in treating cardiac hypertrophy and controlling the occurrence and progression of the cardiac hypertrophy has been demonstrated. Provided are a novel drug target and strategy for the treatment of cardiac hypertrophy, which can reduce the expression of cardiac hypertrophy biomarkers, decrease cardiomyocyte size, improve the ejection fraction and fractional shortening of the heart, lower the heart weight-to-body weight ratio, and mitigate the degree of cardiac fibrosis. In addition, the mechanism of action of PXDC1 in cardiac hypertrophy has been elucidated, deepening the understanding of the pathogenesis of the disease, and laying an important foundation for further exploration of cell biological and molecular biological processes related to cardiac hypertrophy.

Cardiovascular disease methylation marker and application thereof

Publication No.:  CN122855651A 02/10/2026
Applicant: 
SHENZHEN JIYINJIA BIOTECHNOLOGY CO LTD
JIYINJIA BIOMEDICAL TECH SHAOXING CO LTD
\u6DF1\u5733\u5409\u56E0\u52A0\u751F\u7269\u79D1\u6280\u6709\u9650\u516C\u53F8
\u5409\u56E0\u52A0\u751F\u7269\u533B\u5B66\u79D1\u6280\uFF08\u7ECD\u5174\uFF09\u6709\u9650\u516C\u53F8
CN_122855651_A

Absstract of: CN122855651A

The invention belongs to the technical field of biomedicine, and particularly relates to a cardiovascular disease methylation marker and application thereof. The invention discloses a cardiovascular disease methylation marker for the first time. The cardiovascular disease methylation marker comprises a coronary artery endothelial cell methylation marker, a coronary artery smooth muscle cell methylation marker, a myocardial cell methylation marker and/or a heart fiber cell methylation marker. The method can be used for diagnosis, screening or risk stratification of cardiovascular diseases.

METHODS AND AGENTS FOR ASSESSING AND PROMOTING MICROVASCULARIZATION

Publication No.:  WO2026199076A1 01/10/2026
Applicant: 
VAL CHUM SOC EN COMMANDITE [CA]
VAL-CHUM, SOCI\u00C9T\u00C9 EN COMMANDITE
WO_2026199076_A1

Absstract of: WO2026199076A1

Microvascular dysfunction has a wide array of clinical presentations, ranging from ischemic heart disease to renal failure, stroke, blindness, pulmonary arterial hypertension, and dementia. Unfortunately, the lack of clinically reliable biomarkers of microvascular injury or dysfunction is a major roadblock for assessing and preventing microvascular rarefaction in patients. Also, currently, there are no medications that can effectively treat and prevent microvascular diseases. The present application discloses methods for treating a microvascular disease and/or dysfunction in a subject based on the administration of miR-423-5p, let-7b-5p, let- 7a-5p, miR-30a-3p and/or let-7c-5p miRNA or RNA interfering agent mimicking one or more of these miRNAs. The present application discloses methods for assessing the risk of suffering from a microvascular disease or dysfunction by measuring the levels of at least one of miR-423-5p, let-7b-5p, let-7a-5p, miR-30a-3p and/or let-7c-5p miRNA in a sample.

Application of reagent for detecting marker THBS1 in preparation of diagnostic reagent for type 2 cardiorenal syndrome

Publication No.:  CN122833163A 29/09/2026
Applicant: 
AFFILIATED TONGJI HOSPITAL OF TONGJI MEDICAL COLLEGE OF HUAZHONG UNIV OF SCIENCE & TECHNOLOGY
\u534E\u4E2D\u79D1\u6280\u5927\u5B66\u540C\u6D4E\u533B\u5B66\u9662\u9644\u5C5E\u540C\u6D4E\u533B\u9662
CN_122833163_PA

Absstract of: CN122833163A

The invention belongs to the technical field of disease diagnostic reagents, and relates to application of a reagent for detecting a marker THBS1 in preparation of a diagnostic reagent for type 2 cardiac and renal syndromes. Aiming at the problems of difficult diagnosis and insufficient risk assessment of the type 2 cardiac and renal syndrome in the prior art, a new biomarker THBS1 is found, and the correlation between the marker and the attack of the type 2 cardiac and renal syndrome is confirmed; therefore, a reagent for detecting the marker THBS1 can be used for preparing related reagents for diagnosing the type 2 cardiac and renal syndrome and/or evaluating prognosis of the type 2 cardiac and renal syndrome. An animal model finds that the THBS1 level in mouse plasma of a type 2 heart and kidney syndrome model is remarkably increased, and the THBS1 can be used as a biomarker for diagnosing the type 2 heart and kidney syndrome disease. Therefore, the detection of the THBS1 level in the plasma can be used for assisting the diagnosis of the type 2 cardiac and renal syndrome or the evaluation of the prognosis of the type 2 cardiac and renal syndrome.

CD9-based PASC-related cardiovascular system symptom risk assessment application

Publication No.:  CN122833160A 29/09/2026
Applicant: 
CHINA JAPAN FRIENDSHIP HOSPITAL CHINA JAPAN FRIENDSHIP INST OF CLINICAL MEDICINE
\u4E2D\u65E5\u53CB\u597D\u533B\u9662\uFF08\u4E2D\u65E5\u53CB\u597D\u4E34\u5E8A\u533B\u5B66\u7814\u7A76\u6240\uFF09
CN_122833160_PA

Absstract of: CN122833160A

The invention relates to the technical field of biological medicine, in particular to CD9-based PASC related cardiovascular system symptom risk assessment application. The invention provides a risk assessment system taking CD9 as a core molecular marker, and the system can provide objective and quantifiable molecular-level reference basis for risk assessment of PASC-related cardiovascular system symptoms under the condition that sufficient interpretation is difficult to provide by a conventional detection means.

Coronary heart disease methylation marker and application thereof

Publication No.:  CN122811359A 25/09/2026
Applicant: 
FUWAI HOSPITAL CHINESE ACAD OF MEDICAL SCIENCES
BEIJING GENEPLUS TECH CO LTD
\u4E2D\u56FD\u533B\u5B66\u79D1\u5B66\u9662\u961C\u5916\u533B\u9662
\u5317\u4EAC\u5409\u56E0\u52A0\u79D1\u6280\u6709\u9650\u516C\u53F8
CN_122811359_PA

Absstract of: CN122811359A

The invention belongs to the technical field of biomedicine, and particularly relates to a coronary heart disease methylation marker and application thereof. The invention discloses the coronary heart disease methylation marker for the first time, and the coronary heart disease methylation marker can be used for diagnosis, screening or risk stratification of coronary heart disease.

Primer probe composition and kit for direct expansion detection of gene polymorphism of hypertension medication and application method of primer probe composition

Publication No.:  CN122811357A 25/09/2026
Applicant: 
NANCHANG MINGSHUO SHENGKE BIOLOGICAL ENG CO LTD
JIANGXI NANXING MEDICAL TECH CO LTD
SHENZHEN PEOPLES HOSPITAL
JIANGXI CENTER FOR DRUG CONTROL
\u5357\u660C\u94ED\u7855\u751F\u79D1\u751F\u7269\u5DE5\u7A0B\u6709\u9650\u516C\u53F8
\u6C5F\u897F\u5357\u5174\u533B\u7597\u79D1\u6280\u6709\u9650\u516C\u53F8
\u6DF1\u5733\u5E02\u4EBA\u6C11\u533B\u9662
\u6C5F\u897F\u7701\u836F\u54C1\u68C0\u67E5\u5458\u4E2D\u5FC3
CN_122811357_PA

Absstract of: CN122811357A

The invention provides a primer probe composition and a kit for direct expansion detection of gene polymorphism of hypertension medication and an application method, and belongs to the technical field of molecular biology and in-vitro diagnosis. According to the present invention, the combination of the specific primer and the fluorescent probe is designed according to five hypertension clinical core medication gene loci such as ACE-rs1799752, AGTR1-rs5186, ADRB1-rs1801253, CYP2D6 * 10-rs1065852 and CYP2C9 * 3-rs1057910; whole blood direct expansion PCR and a fluorescent probe melting curve technology are combined, and five-site gene polymorphism detection is synchronously completed through a single reaction tube. According to the scheme, nucleic acid extraction and purification do not need to be carried out on a blood sample, closed tube operation is carried out in the whole process, aerosol cross contamination is effectively avoided, and the kit has the advantages of being easy and convenient to operate, rapid in detection, low in cost and accurate in typing, can be matched with a conventional fluorescent quantitative PCR instrument and provides a reliable molecular diagnosis basis for clinical hypertension precise medication.

Blood proteomic marker for cerebral apoplexy and method thereof

Publication No.:  CN122826463A 25/09/2026
Applicant: 
THE UNIV OF HONG KONG
\u9999\u6E2F\u5927\u5B66
CN_122826463_A

Absstract of: CN122826463A

Compositions and methods are provided for evaluating patients suffering from suspected cerebral stroke in order to diagnostically differentiate acute ischemic cerebral stroke and subgroups thereof from intracerebral hemorrhage, transient cerebral ischemic attack, and cerebral stroke mimic disease; to predict responsiveness to treatment and adverse reactions after treatment; and predicting the possibility, life quality and survival rate of subsequent cerebral apoplexy.

PROGNOSTIC AND PREDICTIVE VALUE OF ENDOTHELIAL DYSFUNCTION BIOMARKERS IN SEPSIS-ASSOCIATED ACUTE KIDNEY INJURY

Publication No.:  US20260287596A1 24/09/2026
Applicant: 
CHILDRENS HOSPITAL MEDICAL CENTER [US]
CHILDREN'S HOSPITAL MEDICAL CENTER
US_20260287596_A1

Absstract of: US20260287596A1

Methods and compositions disclosed herein generally relate to methods of identifying, validating, and measuring clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respiratory tract dysfunction, particularly as those responses relate to septic shock in pediatric patients. Certain aspects of the invention relate to identifying one or more biomarkers associated with septic shock in pediatric patients in combination with one or more endothelial-derived biomarkers, receiving a dataset comprising biomarker concentrations, wherein the dataset is from a sample obtained from a pediatric patient having at least one indication of septic shock, then determining whether the biomarker concentrations of each of the at least one biomarkers are greater than one or more pre-determined cut-off biomarker concentration, wherein the level of said biomarker correlates with a predicted outcome.

Treatment of hypertension with Solute Carrier Family 9 Isoform A3 Regulatory Factor 2 (SLC9A3R2) inhibitors

Publication No.:  AU2026223366A1 24/09/2026
Applicant: 
REGENERON PHARMACEUTICALS INC
REGENERON PHARMACEUTICALS, INC.
AU_2026223366_A1

Absstract of: AU2026223366A1

% % $* $ + ($ + % $* $ ( $ + % $!, - % ./%0$ - 1!#,.02 % Abstract ug b s t r a c t u g

USE OF GADD45G AS BIOMARKER FOR CARDIAC HYPERTROPHY AND HEART FAILURE AND USE OF GADD45G IN DEVELOPMENT OF THERAPEUTIC DRUGS

Publication No.:  WO2026194092A1 24/09/2026
Applicant: 
FUWAI HOSPITAL CHINESE ACAD OF MEDICAL SCIENCES SHENZHEN HOSPITAL SHENZHEN SUN YAT SEN CARDIOVASCULA [CN]
\u4E2D\u56FD\u533B\u5B66\u79D1\u5B66\u9662\u961C\u5916\u533B\u9662\u6DF1\u5733\u533B\u9662\uFF08\u6DF1\u5733\u5E02\u5B59\u9038\u4ED9\u5FC3\u8840\u7BA1\u533B\u9662\uFF09
WO_2026194092_A1

Absstract of: WO2026194092A1

Provided is a use of Gadd45g as a biomarker for cardiac hypertrophy. Provided is a use of a substance capable of reducing the activity and/or expression level of Gadd45g in peripheral blood and/or myocardial tissue. Further provided is a use of a substance targeting Gadd45g in the preparation of products. Provided is a use of mice having reduced Gadd45g activity and/or expression level in the preparation and/or screening of drugs. Provided is a kit for detecting Gadd45g.

Application of GLUD1 inhibitor in preparation of medicine for delaying atherosclerosis

Publication No.:  CN122786494A 22/09/2026
Applicant: 
ZHEJIANG UNIV
\u6D59\u6C5F\u5927\u5B66
CN_122786494_PA

Absstract of: CN122786494A

The invention discloses application of a GLUD1 inhibitor in preparation of a medicine for preventing and treating atherosclerosis. According to the application disclosed by the invention, the research finds that in an atherosclerosis model, the macrophage GLUD1 gene is remarkably up-regulated, which indicates that the GLUD1 gene can be used as a diagnosis marker of atherosclerosis, and the diagnosis of atherosclerosis can be quickly realized by detecting the expression level of the GLUD1 gene; the invention provides a new target for atherosclerosis treatment, opens up a new path and a new method, and brings inestimable benefits for delaying atherosclerosis and improving the living quality of patients.

Pharmaceutical application of substance for inhibiting NRDE2

Publication No.:  CN122786495A 22/09/2026
Applicant: 
NANJING MEDICAL UNIV
\u5357\u4EAC\u533B\u79D1\u5927\u5B66
CN_122786495_PA

Absstract of: CN122786495A

The invention discloses a pharmaceutical application of a substance for inhibiting NRDE2. The invention also discloses an application of a substance for knocking out the NRDE2 gene or inhibiting NRDE2 expression in preparation of a medicine for treating atherosclerosis. The NRDE2 is inhibited or knocked out, so that the plaque area can be reduced, the plaque stability can be improved, macrophage inflammation and aging can be inhibited, and the R-loop level can be reduced.

Multi-site gene detection combination for coronary heart disease risk assessment and detection method thereof

Publication No.:  CN122772978A 18/09/2026
Applicant: 
THE FIRST AFFILIATED HOSPITAL OF BENGBU MEDICAL UNIV AFFILIATED TUMOR HOSPITAL OF BENGBU MEDICAL UNI
\u868C\u57E0\u533B\u79D1\u5927\u5B66\u7B2C\u4E00\u9644\u5C5E\u533B\u9662\uFF08\u868C\u57E0\u533B\u79D1\u5927\u5B66\u9644\u5C5E\u80BF\u7624\u533B\u9662\uFF09
CN_122772978_PA

Absstract of: CN122772978A

The invention belongs to the technical field of molecular detection, and discloses a multi-site gene detection combination for coronary heart disease risk assessment and a detection method thereof, the detection combination comprises a PCR amplification primer pair and a corresponding single base extension primer, the PCR amplification primer pair is used for detecting 22 SNP sites of 16 coronary heart disease related genes, and the genes comprise PCSK9, APOE, APOB, MTHFR, LPL, LDLR, SLCO1B1, OLR1, ZPR1, CELSR2, ABCG8, SLC22A1, HFE, MYLIP, ST3GAL4 and NYNRIN. The detection method comprises the following steps: extracting genome DNA of a to-be-detected sample, carrying out multiple PCR amplification, single base extension and mass spectrometry detection, and carrying out coronary heart disease risk assessment according to a genotyping result. The method has the advantages of high detection flux, low cost, short period, good accuracy and suitability for clinical screening.

SERPING1-based PASC-related cardiovascular system symptom risk assessment application

Publication No.:  CN122772974A 18/09/2026
Applicant: 
CHINA JAPAN FRIENDSHIP HOSPITAL CHINA JAPAN FRIENDSHIP INST OF CLINICAL MEDICINE
\u4E2D\u65E5\u53CB\u597D\u533B\u9662\uFF08\u4E2D\u65E5\u53CB\u597D\u4E34\u5E8A\u533B\u5B66\u7814\u7A76\u6240\uFF09
CN_122772974_PA

Absstract of: CN122772974A

The invention relates to the technical field of biological medicine, in particular to application of SERPING1-based PASC related cardiovascular system symptom risk assessment. The invention provides a risk assessment system taking SERPING1 as a core molecular marker, and the system can provide objective and quantifiable molecular level reference basis for risk assessment of PASC-related cardiovascular system symptoms under the condition that sufficient explanation is difficult to provide by a conventional detection means.

Small molecule composition based on quantitative partial reprogramming, application of small molecule composition in prevention and treatment of myocardial infarction and evaluation system

Nº publicación: CN122768250A 18/09/2026

Applicant:

ZHUHAI HENGQIN AONA REGENERATIVE MEDICINE CO LTD
\u73E0\u6D77\u6A2A\u7434\u5965\u7EB3\u518D\u751F\u533B\u5B66\u6709\u9650\u516C\u53F8

CN_122768250_A

Absstract of: CN122768250A

The invention relates to the technical field of biomedical engineering, in particular to a small molecule composition based on quantitative partial reprogramming, application of the small molecule composition in prevention and treatment of myocardial infarction and an evaluation system. The invention provides a small molecule composition for preventing and treating myocardial infarction. The small molecule composition is prepared from sodium valproate, CHIR99021, Repsox, trans-benzene ring propylamine hydrochloride and forskolin. According to the application disclosed by the invention, a'myocardial epigenetic remodeling safe treatment window '(52-72%) applied to myocardial tissue repair is defined for the first time, and a rat myocardial infarction model is utilized to prove that when the epigenetic age reversal amplitude falls into the window, the most obvious exercise tolerance improvement and the highest 90-day cumulative survival rate can be synchronously obtained; and a clear quantification boundary and end point verification basis is provided for safe application of a partial reprogramming technology in cardiac regenerative medicine.

traducir